Dr. George Talks About New Data on Checkpoint Inhibitors

In this video, Daniel George, MD, Director, Prostate Clinic, Genitourinary Oncology, Duke Cancer Institute, shares his thoughts on the most exciting data to be presented on immunotherapies at the ASCO Annual Meeting 2013.

In this video, Daniel George, MD, Director, Prostate Clinic, Genitourinary Oncology, Duke Cancer Institute, shares his thoughts on the most exciting data to be presented on immunotherapies at the ASCO Annual Meeting 2013. A number of abstracts will be presented on both single agent and combinations of checkpoint inhibitors. Specifically, there is a Phase I study from Memorial Sloan-Kettering and Yale demonstrating a depth of response with the combination of ipilimumab and nivolumab for the treatment of melanoma. Dr George notes that this trial demonstrates "just how robust immunotherapy can be."

This video was taken on June 1, 2013, at the ASCO Annual Meeting 2013 in Chicago, IL.